Ginkgo Bioworks director sells 5,000 shares

Ginkgo Bioworks Holdings, Inc. (DNA) director Henry Christian O reported selling 5,000 shares of Class A Common Stock on September 15, 2026 in an open-market or private transaction at a weighted average price of $7.081 per share.

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) director Henry Christian O reported selling 5,000 shares of Class A Common Stock on September 15, 2026 in an open-market or private transaction at a weighted average price of $7.081 per share. After this sale, he holds 19,310 shares directly. No Rule 10b5-1 trading plan is indicated.

The filing notes the shares were sold in multiple trades at prices ranging from $7.074 to $7.085 per share, and the reporting person has undertaken to provide full breakdowns of the individual trade prices and sizes upon request.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider HENRY CHRISTIAN O

Role Director

Sold 5,000 shs ($35K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1	5,000	$7.081	$35K

Holdings After Transaction: Class A Common Stock — 19,310 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.074 to $7.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $7.081 per share Post-transaction holdings: 19,310 shares +1 more

4 metrics

Shares sold 5,000 shares Class A Common Stock sold on September 15, 2026

Weighted average sale price $7.081 per share Average price for the 5,000 shares sold

Post-transaction holdings 19,310 shares Direct Class A Common Stock holdings after the sale

Sale price range $7.074–$7.085 per share Range of prices for multiple trades within the reported sale

Key Terms

Class A Common Stock, weighted average price, Rule 10b5-1

3 terms

Class A Common Stock financial

"reported selling 5,000 shares of Class A Common Stock on September 15, 2026"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

weighted average price financial

"at a weighted average price of $7.081 per share"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is indicated."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did DNA report for director Henry Christian O?

He reported a sale of 5,000 shares of Ginkgo Bioworks Class A Common Stock on September 15, 2026, executed as an open-market or private transaction at a weighted average price of $7.081 per share.

How many Ginkgo Bioworks (DNA) shares does Henry Christian O hold after this Form 4 transaction?

After the reported sale, Henry Christian O directly holds 19,310 shares of Ginkgo Bioworks Holdings, Inc. Class A Common Stock, as stated in the Form 4 filing.

At what prices were the DNA shares sold in Henry Christian O’s September 15, 2026 transaction?

The filing states the shares were sold at a weighted average price of $7.081 per share, in multiple trades with individual prices ranging from $7.074 to $7.085 per share.

Was the September 15, 2026 DNA insider sale under a Rule 10b5-1 trading plan?

The Form 4 indicates no Rule 10b5-1 trading plan; the document-level checkbox for trades under such a plan is not marked, and the footnote does not describe the sale as pursuant to a trading plan.

What security class is involved in the Ginkgo Bioworks (DNA) Form 4 for Henry Christian O?

The transaction involves Class A Common Stock of Ginkgo Bioworks Holdings, Inc., as specified in the Form 4 for the September 15, 2026 sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:07 PM Accepted by SEC EDGAR 09/16/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENRY CHRISTIAN O

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/15/2026		S		5,000	D	$7.081(1)	19,310	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.074 to $7.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Remarks:

	/s/ Karen Tepichin, Attorney-in-Fact	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)